Masatake Matsuoka1,2, Masanori Okamoto1,3, Tamotsu Soma1, Isao Yokota4, Ryuta Arai1, Tomohiro Onodera2, Eiji Kondo5, Norimasa Iwasaki2, Hiroaki Hiraga1. 1. Department of Musculoskeletal Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan. 2. Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 3. Department of Orthopaedic Surgery, Shinshu University School of Medicine, Nagano, Japan. 4. Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 5. Centre for Sports Medicine, Hokkaido University Hospital, Sapporo, Japan.
Abstract
Background/Aim: Although smoking history is predictive of poor pulmonary metastasis-free survival (PMFS) in patients with epithelial tumors, the impact of smoking history on PMFS in those with soft-tissue sarcoma (STS) is not known. Patients and Methods: Patients undergoing treatment for STS at our institutes between 2008 and 2017 were enrolled. Patients were excluded if they had metastatic lesion, or had a histopathological classification demonstrating small round-cell sarcoma. The impact of smoking history on PMFS and overall survival was examined with multivariate analysis using a Cox proportional hazards model. Results: A total of 250 patients were retrospectively reviewed. Patients with smoking history had worse PMFS on multivariate analysis (hazard ratio=2.00, 95% confidence interval=1.12-3.60). On the other hand, smoking history did not significantly affect overall survival (hazard ratio=1.26, 95% confidence interval=0.61-2.58). Conclusion: Patients with STS need to be followed-up by frequent clinical assessments if they have a smoking history. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: Although smoking history is predictive of poor pulmonary metastasis-free survival (PMFS) in patients with epithelial tumors, the impact of smoking history on PMFS in those with soft-tissue sarcoma (STS) is not known. Patients and Methods: Patients undergoing treatment for STS at our institutes between 2008 and 2017 were enrolled. Patients were excluded if they had metastatic lesion, or had a histopathological classification demonstrating small round-cell sarcoma. The impact of smoking history on PMFS and overall survival was examined with multivariate analysis using a Cox proportional hazards model. Results: A total of 250 patients were retrospectively reviewed. Patients with smoking history had worse PMFS on multivariate analysis (hazard ratio=2.00, 95% confidence interval=1.12-3.60). On the other hand, smoking history did not significantly affect overall survival (hazard ratio=1.26, 95% confidence interval=0.61-2.58). Conclusion: Patients with STS need to be followed-up by frequent clinical assessments if they have a smoking history. Copyright 2021, International Institute of Anticancer Research.
Authors: M Trojani; G Contesso; J M Coindre; J Rouesse; N B Bui; A de Mascarel; J F Goussot; M David; F Bonichon; C Lagarde Journal: Int J Cancer Date: 1984-01-15 Impact factor: 7.396
Authors: Alex H Krist; Karina W Davidson; Carol M Mangione; Michael J Barry; Michael Cabana; Aaron B Caughey; Esa M Davis; Katrina E Donahue; Chyke A Doubeni; Martha Kubik; C Seth Landefeld; Li Li; Gbenga Ogedegbe; Douglas K Owens; Lori Pbert; Michael Silverstein; James Stevermer; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2021-03-09 Impact factor: 56.272
Authors: Gera Nagelhout; Renée Mf Ebisch; Olga Van Der Hel; Gert-Jan Meerkerk; Tessa Magnée; Thomas De Bruijn; Barbara Van Straaten Journal: Expert Rev Anticancer Ther Date: 2021-03-05 Impact factor: 4.512
Authors: Kevin Ten Haaf; Carlijn M van der Aalst; Harry J de Koning; Rudolf Kaaks; Martin C Tammemägi Journal: Int J Cancer Date: 2021-05-03 Impact factor: 7.396